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Nuclear actin aggregation is a hallmark of
anti-synthetase syndrome–induced
dysimmune myopathy
ABSTRACT
Objective: To analyze antisynthetase syndrome–associated myositis by modern myopathologic
methods and to define its place in the spectrum of idiopathic inflammatory myopathies (IIMs).
Methods: Skeletal muscle biopsies from antisynthetase syndrome–associated myositis and other
IIMs from different institutions worldwide were analyzed by histopathology, quantitative PCR,
and electron microscopy.
Results: Myonuclear actin filament inclusions were identified as a unique morphologic hallmark of
antisynthetase syndrome–associated myositis. Nuclear actin inclusions were never found in der-
matomyositis, polymyositis, sporadic inclusion body myositis, autoimmune necrotizing myopathy
associated with signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A reductase
autoantibodies, or nonspecific myositis associated with other systemic diseases, harboring
myositis-associated autoantibodies, and presenting myofiber necrosis. We show that molecules
involved in actin filament formation and actin shuttling mechanisms are altered in antisynthetase
syndrome, and may thus be involved in pathologic myonuclear actin aggregation. In addition, we
have identified a typical topographic distribution of necrotic myofibers predominantly located at
the periphery of muscle fascicles accompanied by inflammation and destruction of the perimysial
connective tissue.
Conclusion: Antisynthetase syndrome–associated myositis is characterized by distinctive myo-
nuclear actin filament inclusions, including rod formations and a typical necrotizing perimysial
myositis. This supports the hypothesis that antisynthetase syndrome–associated myositis is
unique and should not be grouped among dermatomyositis, polymyositis, sporadic inclusion body
myositis, necrotizing autoimmune myositis, or nonspecific myositis.
Classification of evidence: This study provides Class II evidence that for patients with IIMs, the
presence of myonuclear actin filament inclusions accurately identifies patients with antisynthe-
tase syndrome–associated myositis (sensitivity 81%, specificity 100%). Neurology®
2015;84:1346–1354
GLOSSARY
AARS 5 aminoacyl-transferase RNA synthetase; ASA 5 aminoacyl-transferase RNA synthetase autoantibodies; DM 5 der-
matomyositis; EM 5 electron microscopy; IIM 5 idiopathic inflammatory myopathy; MAA 5 myositis-associated autoanti-
bodies; MHC 5 major histocompatibility complex; NAM 5 necrotizing autoimmune myositis; PM 5 polymyositis; sIBM 5
sporadic inclusion body myositis; tRNA 5 transfer RNA.
Antisynthetase syndrome is a systemic inflammatory disease affecting multiple organs, including
the lung, joints, heart, gastrointestinal organs, skin, and importantly, with high prevalence, skel-
etal muscle. The involvement of various organs may dominate the clinical presentation1;
however, interstitial lung disease and myositis are the most prevalent manifestations of anti-
synthetase syndrome.2 Antisynthetase syndrome is characterized by the presence of one of 8
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aminoacyl-transferase RNA synthetase (AARS)
autoantibodies (ASA) that have been identified
so far in the serum of affected patients. The
elevated serum ASA gives the specific name to
subforms of the disease, e.g., histidyl–transfer
RNA (tRNA) synthetase in Jo-1 syndrome
(formerly PL1 syndrome3).4 The AARS are en-
zymes localized in the cytoplasm, where they
catalyze the ligation of amino acids to their
cognate tRNA and play an essential role in pro-
tein synthesis and cell viability.5 Their relation-
ship to myositis as an autoimmune condition
has been highlighted early on.6,7 Although it is
unclear why AARS are recognized as autoanti-
gens, theories that link ASA to autoimmunity
have been proposed.5 In antisynthetase syn-
drome, myositis may present as either dermat-
omyositis (DM) or polymyositis (PM)8–10;
however, this association seems to be arbitrary,
and is not clinically helpful.
The aim of the present study was to analyze
muscle biopsies from different institutions
worldwide from patients with antisynthetase
syndrome with clinically significant myositis,
using modern molecular, morphologic, and
immunologic methods.
METHODS Patients. Skeletal muscle biopsies from patients
(n 5 21) with antisynthetase syndrome obtained for routine
diagnostic purposes were included in the study. An overview of
relevant clinical features is provided in table e-1 on theNeurology®
Web site at Neurology.org. Five control skeletal muscle
biopsies from patients without any morphologic muscle
abnormalities, normal inflammatory laboratory markers, and
normal CK levels (biopsied for clinically unexplained myalgia)
were also analyzed.
Fourteen muscle samples from patients with sporadic inclu-
sion body myositis (sIBM), DM, and necrotizing autoimmune
myositis (NAM), and 11 samples of nonspecific myositis (classi-
fication based on ENMC11 or Hilton Jones12 criteria, respec-
tively), embedded in araldite, were used for ultrastructural
examination only. All biopsy specimens had been cryopreserved
at 280°C immediately after removal or preserved in glutaralde-
hyde for further ultrastructural analysis prior to diagnostic
workup. These samples were used for studying presence or
absence of actin in myonuclear only.
Standard protocol approvals, registrations, and patient
consents. Informed consent was obtained from all patients
locally and the Charité ethics committee having approved the
study (EA1/204/11).
Primary research question and level of evidence. This
study provides Class II evidence that for patients with idiopathic
inflammatory myopathies (IIMs), the presence of myonuclear
actin filament inclusions accurately identifies patients with anti-
synthetase syndrome–associated myositis (sensitivity 81%, spec-
ificity 100%).
Histology. The 7-mm-thick cryostat sections were stained by
hematoxylin & eosin, modified Gömöri trichrome, for nonspe-
cific esterase, alkaline phosphatase, and various antibodies for
immunohistology (table e-2). We used the same methodology
as previously described13 and detected the antibodies with the
immunoperoxidase method. All staining procedures were per-
formed in the same laboratory with standardized methodologies
on a Benchmark XT immunostainer (Ventana, Tucson, AZ).
Omission of primary antibodies in control sections resulted in
absence of any cellular labeling.
Electron microscopy. Ultrastructural analysis of muscle biopsy
specimens was performed after fixation in 2.5% glutaraldehyde
for 48 hours at 4°C, postfixation in 1% osmium tetroxide, and
embedding of the muscle tissue in araldite. Ultrathin sections
were stained with uranyl acetate and lead citrate. Electron micros-
copy was performed with a Zeiss P902 electron microscope
(Oberkochem, Germany).
Separation of nuclei and cytoplasm. Separation of myonu-
clei from the cytoplasm was performed by using the SurePrep
Nuclear or Cytoplasmic RNA Purification Kit (Fisher Bio-
Reagents, Schwerte, Germany) according to the manufacturer’s
instructions.
Quantitative real-time PCR. After isolation, mRNA was ex-
tracted from nuclei and cytoplasm, using the trizol/chloroform
method according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Further workup for qPCR analysis was performed
as previously described.13 All qPCR assays were purchased from
ABI Biosystems (Life Technologies, Darmstadt, Germany). The
respective identification numbers are as follows: ACTA1 (actin a1):
Hs00559403_m1, ACTR2 (ARP2): Hs00855199_g1, WASL
(N-WASP): Hs00187614_m1, NCK1: Hs0152377_m1,
IPO9 (importin-9): Hs00216375_m1, XPO6 (exportin-6):
Hs00385137_m1, CFL2 (cofilin-2): Hs00368395_g1,
PFN2 (profilin-2): Hs00160050_m1, ACTB (b-actin):
Hs99999903_m1, PGK1: Hs99999906_m1.
Gene expression of the respective molecules was illustrated by
the log10 of RQ values demonstrating the regulation of expres-
sion levels as fold-change compared to the normal controls, with
“0” demonstrating an expression on level equal to healthy con-
trols, 1 ≙ 10-fold increase, 2 ≙ 100-fold increase, and so on.
Calculation of results was performed with the Applied Biosystems
SDS 2.3 and 2.4 software, as well as with the RQ Manager 1.2.1
(both Applied Biosystems/Life Technologies).
Statistics. The Mann-Whitney U test was used for analyses of
quantitative differences of mRNA transcripts. Data are presented
as means with SD. Categorical variables are reported as numbers
or percentages and were compared using a Fisher exact test. The
level of significance was set at p , 0.05. Statistics were calculated
with the software GraphPad Prism 5.02 (GraphPad Software, La
Jolla, CA).
RESULTS Patients and clinical and ancillary data. An
overview of the clinical and laboratory characteristics
of the 21 patients with antisynthetase syndrome
included in this study is presented in table e-1. Of
note, Jo-1 was by far the most frequently
encountered ASA. Patients with anti-PL7 or anti-
PL12 autoantibodies exhibited a similar morphologic
pattern on muscle biopsy. In this series, no other
ASA or multiple ASA were detected. Skeletal muscle
biopsies from patients with sIBM, DM, NAM, and
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nonspecific myositis were included in the
ultrastructural analysis, and no clinical data are
provided for them.
Morphologic analysis.Morphologic analysis, including
ultrastructural examination of skeletal muscle biopsy
specimens from patients with antisynthetase syn-
drome, revealed a very uniform pattern, characterized
by the following features: muscle fibers were generally
rounded and showed variation in fiber size (figure 1,
A and B), harboring internalized nuclei with a
predominance in perifascicular regions, but lacking
significant structural sarcoplasmic abnormalities like
cores or targetoid fibers, rimmed vacuoles, or ragged
red or ragged blue fibers (figure 1C). A diffuse macro-
phagocytic infiltrate was mainly found in the perimy-
sial area of muscle fibers with focal extension into the
endomysium (figure 1D). Interstitial perimysial and
endomysial connective tissue was heavily fragmented,
as visualized by Gömöri trichrome and elastica van
Gieson (figure 1, A and E). Alkaline phosphatase
activity was particularly notable in the perimysium
(figure 1F). Perimysial macrophages were accompa-
nied mainly by a CD81 lymphocytic infiltrate,
Figure 1 Histology in muscle tissue of patients with antisynthetase syndrome
Rounded muscle fibers show variations in fiber size and numerous perifascicular necrotic fibers illustrated by modified Gö-
möri trichrome and (B) by a combined dystrophin eosin stain. Fibers lacked sarcoplasmic structural abnormalities (C, COX-
SDH). CD681 macrophages were mainly found in the perimysial area of muscle fibers with focal extension into the endo-
mysium (D). Interstitial connective tissue fragmentation as visualized by Gömöri trichrome (A) and elastica van Gieson (E).
Alkaline phosphatase activity was particularly notable in the perimysium (F).
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which also localized around small vessels, and
extended focally into the endomysium (figure 2A).
CD1381 plasma cells were mainly detectable around
blood vessels of the perimysium (figure 2B). Myofiber
necrosis accompanied by myophagocytosis was a
prominent finding, especially along the periphery of
fascicles (figure 1, A, B, E, F). Additionally, major
histocompatibility complex (MHC) class I and MHC
class II staining on the sarcolemma with perifascicular
predominance was often identified (figure 2, C and D).
Deposition of the C5b-9 complex was detected on
the sarcolemma of numerous fibers in the perimysial
area, and numerous necrotic fibers accumulated
C5b-9 in the sarcoplasm as well (nonspecific),
predominantly in the perimysial area (figure 2E).
Significant regeneration was highlighted by neonatal
myosin (not shown) and neural cell adhesion molecule
staining (figure 2F).
Ultrastructural analysis revealed nuclear filamen-
tous inclusions (figure 3, A and B), composed of
Figure 2 Immunohistochemical features in muscle tissue of patients with antisynthetase syndrome
Perimysial macrophages were accompanied mainly by a CD81 lymphocytic infiltrate, which also localized around small
vessels, and extended focally into the endomysium (A). CD1381 plasma cells were mainly detectable around blood vessels
of the perimysium (B). Additionally, major histocompatibility complex (MHC) class I and MHC class II staining on the sarco-
lemma with perifascicular predominance was often identified (C, D). Deposition of C5b-9 (MAC) was detected on the sar-
colemma of numerous fibers in the perimysial area, and numerous necrotic fibers accumulated C5b-9 in the sarcoplasm
predominantly in the perimysial area as well (E, C5b-9). Significant regeneration was highlighted by, e.g., neural cell adhesion
molecule staining (F). (All photomicrographs: original magnification 2003.)
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filaments of 7 mm length and a diameter ofz20 nm;
these inclusions very likely correspond to bundles of
actin filaments (figure 3C). This hypothesis was con-
firmed by prominent immunoreactivity of nuclear in-
clusions of the same shape in the same biopsies using
antibodies against sarcomeric actin (figure 3D).
Moreover, the inclusions were also immunoreactive
with an anti-2G2 serum that specifically stains
nuclear G-actin (figure 3E), while the corresponding
epitope in cytoplasmic actin filaments was nonreac-
tive.14,15 These inclusions were regularly found in all
but 4 biopsy specimens (81%) by electron micros-
copy (EM) and also by semithin sections (figure 3F),
but with high interindividual frequency (between
2% and 30% of nuclei). In single cases, EM also
evidenced nuclear I-band/Z-band/I-band–like com-
plexes (figure 3G) and nuclear rods (figure 3H). The
myonuclei of muscle fibers adjacent to the perimy-
sium were most affected. Nuclei of other cells (e.g.,
endothelial cells, satellite cells, or fibroblasts) did not
show nuclear actin aggregates. Approximately 300
nuclei were examined in each patient’s biopsy. In
addition, 3 of our patients harbored tubuloreticular
inclusions in endothelial cells.
Next, we tested if myonuclear aggregates were pre-
sent in other IIMs: myonuclear actin aggregates were
not observed at the ultrastructural level in (1) 14 biop-
sies from adult patients with classical DM, who did not
harbor ASA, diagnosed according to ENMC criteria11;
(2) 14 muscle biopsies from patients with sIBM; (3)
biopsies from 14 patients with NAM; or (4) biopsies
from 11 patients with nonspecific myositis with
myositis-associated autoantibodies (MAA) (p , 0.0001
vs antisynthetase syndrome patients). This indicates that
nuclear actin aggregates are highly specific (93.3%) for
antisynthetase syndrome–associated myositis, while the
sensitivity is 80.1%.
Molecular analysis of myonuclear actin aggregation in
antisynthetase syndrome. Since myonuclear actin
aggregates were detected in a significant proportion
of muscle biopsies from patients with antisynthetase
syndrome, molecules involved in actin aggregation
were studied in the nuclear and sarcoplasmic fractions
of skeletal muscle after isolation of RNA of the
respective cellular compartments (figure 4A). First,
the presence of actin, both in the nucleus and the
cytoplasm, was measured by gene expression of
ACTA1 (actin a1) via qPCR. These results confirmed
the presence of actin mRNA in both compartments,
and revealed that actin was significantly reduced both
in the cytoplasm and in the nucleus, while nuclear
and cytoplasmic ACTB (b-actin) was elevated and
expressed at similar levels. Gene expression of mole-
cules involved in actin filament formation, bundling,
and nucleation showed that N-WASP (WASL) was
Figure 3 Electron microscopy of muscle tissue of patients with antisynthetase
syndrome
(A–C) Myonuclear actin filament aggregates, overview and illustration of filamentous char-
acter (electron microscopy [EM], original magnification 10,0003, 20,0003, and 50,0003).
(D) Aggregates were sarcomeric actin-positive (original magnification 6003) and (E) nuclear
G-actin illustrated by an anti-2G2 serum (original magnification 2003). (F) Semithin sections
also revealed myonuclear inclusions in a methylene blue (MB) stain (semithin section, MB
original magnification 6003). EM further evidenced nuclear I band/Z band/I band–like com-
plexes (original magnification 10,0003; figure 2G) and nuclear rods (original magnification
20,0003 and 50,0003; G and H).
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expressed at high levels in the nucleus but not in the
cytoplasm of skeletal muscle from patients with anti-
synthetase syndrome, while ACTR2 (Arp2) and
NCK1 were not significantly regulated or expressed
at different levels in the nucleus or the cytoplasm
(figure 4A).
In a second step, 4 molecules involved in the reg-
ulation of actin levels in the nucleus and cytoplasm
were analyzed at the mRNA level. Among these were
the transport proteins importin-9 and exportin-6 and
their cofactors cofilin-2 and profilin-2. The gene expres-
sions of XPO6 (exportin-6) and PFN2 (profilin-2) were
found at significantly elevated levels in the nuclear
or cytoplasmic fractions. Conversely, we showed
that gene expression of CFL2 (cofilin-2) was down-
regulated in the nucleus and cytoplasm, while IPO9
(importin-9) was not modulated in comparison to
normal controls or at different levels in both frac-
tions (figure 4B).
DISCUSSION Accurate identification of the mor-
phologic, molecular, or immunologic mechanisms
underlying different subforms of myositis is of para-
mount importance, in order to understand the path-
ogenesis and prognosis, and ultimately, to develop
effective therapeutic options.
We provide clear evidence that antisynthetase
syndrome–associated myositis is a unique form of
IIM that can be distinguished from dermatomyositis,
autoimmune necrotizing myopathy, nonspecific
myositis, associated with other autoantibodies, e.g.,
MAA, and sIBM. In addition to demonstrating a
uniform and characteristic morphologic pattern of
myositis, we provide molecular data regarding the
pathogenesis of myonuclear actin accumulation.
Accordingly, we expand the in vitro results previously
reported on circumstances that induce presence of
actin and rods in myonuclei.16,17 While these
in vitro results were described as a model for patients
with genetic diseases emphasizing that not all nuclear
rods are the same, we provide evidence that the accu-
mulation and aggregation of actin may occur due to
cell stress in an autoimmune disorder of skeletal mus-
cle, antisynthetase syndrome. We also demonstrate
that absence of elevated actin levels in the nucleus or
the cytoplasm reflects that nuclear actin aggregation
is not due to an increase but rather a dysregulated
aggregation and shuttling of actin.
It is generally accepted that actin is abundant in
the nuclei of numerous cells, including myonuclei.
Actin takes part in a plethora of intracellular molecu-
lar pathways including the organization and reading
of genetic information.18,19 Although there is strong
evidence that actin influences transcription, the
precise molecular mechanisms remain unclear. Also,
the role that actin plays in specific cell types under
certain pathologic conditions, and which form actin
adopts or which are possible binding partners, is
incompletely characterized.
A number of factors are involved in actin filament
formation, bundling, and nucleation.18 Among these,
Arp2/3, an active component of the RNA POL II
transcriptional machinery, drives intranuclear aggre-
gation of de novo actin polymers and branching of
established actin filaments. N-WASP, which is phys-
ically linked to RNA POL II, induces Arp2/3-
mediated actin polymer formation upon activation.18
NCK, a potent N-WASP activator, shuttles in and
out of the nucleus and after induction of DNA
damage it is translocated to the nucleus.20 In our
study, N-WASP was expressed at high levels in the
nuclei compared to the cytoplasm, arguing for a role
Figure 4 Gene expression of nuclear and cytoplasmic fractions in muscle of patients with antisynthetase syndrome
(A, B) Gene expression of nuclear and cytoplasmic fractions of skeletal muscle tissue is measured quantitatively. Genes involved in nuclear aggregation and
transport of actin were analyzed.WASLwas expressed at high levels in the nuclear fraction. XP06 and PFN2were expressed at significantly elevated levels
in the cytoplasm or the nuclei, whereas expression of CFL2 was downregulated and IPO9 was comparable in both compartments and not differentially
regulated when compared to healthy control levels.
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in actin polymerization, while Arp2/3 itself was not
expressed at significantly different levels in the nuclei
and cytoplasm. Also, NCK levels were similar in both
compartments, showing that molecules involved in
the activation of N-WASP were not altered. We
therefore hypothesized that the ability of actin to
polymerize, and form bundles in the nucleus, may
be a relevant pathogenic mechanism that underlies
the ultrastructural observation of nuclear actin aggre-
gation in antisynthetase syndrome.
Exportin-6 is involved in the removal of actin
from the nucleus,18 and recognizes 1:1 complexes of
actin/profilin, the latter being an actin-binding pro-
tein that indirectly promotes actin polymer forma-
tion. In addition, the inhibition of exportin-6
expression by RNA interference resulted in the
nuclear accumulation of actin and formation of
rods.21 These in vitro results made it likely that
exportin-6 may be involved in the pathogenesis of
nuclear action aggregation and in rod formation
observed in antisynthetase syndrome. Interestingly,
both profilin 2, the cofactor of exportin-6, and
exportin-6 itself, were expressed at elevated levels,
indicating an increased transcription of molecules
involved in the export of actin-profilin complexes
from the nucleus.
Cofilin-2 serves actin polymers, binding both
monomeric and polymeric actin, and is coimported
with actin. Upon dephosphorylation, actin-cofilin
complexes are imported into the nucleus via a nuclear
localization sequence, a mechanism that is also
involved in rod formation upon cell stress.22 Down-
regulation of cofilin-2 expression in the nuclei of my-
ofibers may thus result in reduced or impaired
shuttling of actin into the nucleus. However, the
expression of importin-9, which is required to main-
tain nuclear actin levels, by interacting both with
cofilin-2 and actin, was not altered. Overall, import
and export shuttling mechanisms and mechanisms of
actin aggregation are impaired in muscle fibers of
patients with antisynthetase syndrome.
There are several lines of evidence that explain
why and how actin and actin aggregation may be
linked to inflammation-induced cell stress. Interest-
ingly, actin bundle formation in nuclei upon cellular
stress is an evolutionally highly conserved process,23
and macrophages have been implicated in actin
homeostasis.24 Importantly, it has been reported that
stress induced by heat shock treatment of cells caused
the accumulation of nuclear actin and nuclear rod
formation.22,25
Of note, myonuclear aggregates have been rarely
described in other diseases. However, they appear mor-
phologically distinct in oculopharyngeal muscular dys-
trophy.26 Furthermore, intranuclear rod formation has
also been described in sporadic late-onset nemaline
myopathy,27 a rare condition also considered to be
immune-mediated.28 In patients with PLEC1 (Plectin)
and LDB3 (Zasp) mutations, nuclear rods have also
been described.29,30 To our knowledge, there are no
reports describing actin aggregation in the context of
diseases of the skeletal muscle otherwise.
In antisynthetase syndrome, myositis has been
attributed to PM or DM or has been associated with
an amyopathic form of DM,31–33 which may cause
considerable confusion since the mechanisms and
features of myofiber injury are largely unknown.
Mozafar and Pestronk34,35 have highlighted the
fragmentation of perimysial connective tissue and
perimysial inflammation in 11 Jo-1 patients, conclud-
ing that this disease is paradigmatic of inflammatory
myopathy with perimysial pathology. Our results
expand these findings by providing evidence for char-
acteristic ultrastructural alterations and molecular
underpinnings.
Myonuclear actin filament aggregates were not
detected in 4 of 21 of antisynthetase syndrome
patients’ muscle biopsy specimens. These cases
showed remarkably few inflammatory infiltrates, very
little or no fragmentation of the perimysium, and
absent or sparse necrotic myofibers. Along that line,
it has been shown that the ASA may be detected in
the sera of patients before the onset of clinically man-
ifest myositis.36 This observation may explain why
some patients may not yet have developed the full-
blown morphologic picture of the condition. Further-
more, it is not known if anti-inflammatory therapy
may influence the formation of myonuclear actin
inclusions.
In this study, we provide evidence that myonu-
clear actin aggregation and intranuclear rod formation
specifically define antisynthetase syndrome. Accord-
ingly, we recommend ultrastructural examination of
muscle biopsies from patients with ASA, to confirm
whether myonuclear actin inclusions represent
a pathognomonic feature of the antisynthetase
syndrome–associated myositis entity similar to tubu-
loreticular inclusions in DM. Alternatively, examina-
tion of methylene blue–stained semithin sections or
immunostaining with the 2G2 antibody could
become a diagnostic feature as well. Actin aggregation
and transport mechanisms should be studied in fur-
ther samples in the future to increase statistical power.
Based on our results, we conclude that antisynthetase
syndrome–associated myositis should be considered a
separate subform of IIMs.
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